Lobeline for smoking cessation

Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. The objective of this review was to assess the effects of lobeline on long term smoking cessation. We searched the Cochrane Tobacco Addiction Group trials register (m...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews no. 2; p. CD000124
Main Authors: Stead, Lindsay F, Hughes, John R
Format: Journal Article
Language:English
Published: England 15.02.2012
Subjects:
ISSN:1469-493X, 1469-493X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. The objective of this review was to assess the effects of lobeline on long term smoking cessation. We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011). Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence. There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:1469-493X
1469-493X
DOI:10.1002/14651858.CD000124.pub2